Table 1 Main IgG autoantibodies found in patients with post-COVID syndrome
Autoantibody | N: 100 | Reported in COVID-19a |
|---|---|---|
Anti-Tg | 14 (14.0%) | Yes |
Anti-CENP-B, CENP-A | 9 (9.0%) | Yes |
Anti-IFN-αF | 9 (9.0%) | Yes |
Anti-IFN-α4B | 8 (8.0%) | Yes |
Anti-IFN-αD | 8 (8.0%) | Yes |
Anti-IFN-αI | 8 (8.0%) | Yes |
Anti-IFN-αJ1 | 8 (8.0%) | Yes |
Anti-GAD65 | 7 (7.0%) | Yes |
Anti-IFN-αC | 7 (7.0%) | Yes |
Anti-IFN-αH2 | 7 (7.0%) | Yes |
Anti-IFN-αWa | 7 (7.0%) | Yes |
Anti-IFN- ω | 7 (7.0%) | Yes |
Anti-La/SS-B | 7 (7.0%) | Yes |
Anti-IFN-αB2 | 6 (6.0%) | Yes |
Anti-IFN-αK | 6 (6.0%) | Yes |
Anti- IFN-λ1 | 6 (6.0%) | Yes |
Anti-Ku (p70/p80) | 6 (6.0%) | Yes |
Anti-MDA5 | 6 (6.0%) | Yes |
Anti-PL-7 | 6 (6.0%) | Yes |
Anti-U1-snRNP (68, A, C, B) | 6 (6.0%) | Yes |
Anti-Histone | 5 (5.0%) | Yes |
Anti-IFN-αG | 5 (5.0%) | Yes |
Anti-IFN-β, IFN-β1 | 5 (5.0%) | Yes |
Anti-PM/Scl75 | 5 (5.0%) | Yes |
Anti-CD8B | 18 (18.0%) | No |
Anti-IL-2 | 10 (10.0%) | No |
Anti-Collagen V | 8 (8.0%) | No |
Anti-IFN-αA | 8 (8.0%) | No |
Anti-Aldolase C | 6 (6.0%) | No |
Anti-IL-17F | 6 (6.0%) | No |
Anti-SRP54 | 6 (6.0%) | No |
Anti-PTH | 5 (5.0%) | No |